Contact Sales

Meet the Team

We are the imaging software people.

Gene Saragnese

Prior to joining the Mirada Medical board as Chairman, Gene Saragnese served as the Philips Healthcare CEO of Philips Imaging Systems from April 2009 until May 2015. Before joining Philips, Mr. Saragnese served as GE Healthcare’s Vice President and General Manager of Molecular Imaging and Computed Tomography. Prior to that, he served as Chief Technology Officer for GE Healthcare. In this role, Mr. Saragnese led Global Product Development Engineering and Component Operations around the world, including Corporate Research sites in New York, China, India and Germany. He has also served as General Manager for GE Medical Systems’ Global MRI business and the leader for GE Medical Systems’ Global MRI Engineering organization. Prior to his career in healthcare, Mr. Saragnese held management roles with GE, RCA, Martin Marietta and Lockheed Martin in the aerospace industry. He is a graduate of Rutgers College of Engineering in New Jersey

Hugh Bettesworth

Hugh Bettesworth has worked in the software industry for over fifteen years, the last twelve in the clinical sector. He joined Mirada in 2001, and took over the development of the company’s image fusion product lines in 2003. Following Mirada’s acquisition by first CTI Molecular Imaging and then Siemens Molecular Imaging, Hugh continued to develop the market for these products, focusing on the delivery of specialist molecular imaging workflows into new markets and in particular the PACS market. He led a management buyout in 2008 which re-established Mirada’s independent status and provided the platform for the innovative software developments that have resulted in Mirada’s subsequent growth and leading technical position today.

Prof. Sir Michael Brady

Prof. Sir Michael Brady FRS, FREng, FMedSci is now Professor of Oncological Imaging in the Department of Oncology at the University of Oxford, having retired in 2010 as Professor of Information Engineering. He is co-Director of the Oxford Cancer Imaging Centre. He combines his work in oncology with a range of entrepreneurial activities. He is Deputy Chairman of Oxford Instruments plc. and also a founding director of successful startup companies such as Guidance and, of course, Mirada Medical. He was elected an Honorary Fellow of the IET and Institute of Physics. He was awarded the IEE Faraday Medal in 2000 and also the IEEE Third Millennium Medal for the UK. In 2005 the Royal Institution awarded Professor Sir Michael Brady the Henry Dale Prize for “outstanding work on a biological topic by means of an original multidisciplinary approach”.

David Gudgin

David Gudgin qualified as a management accountant with ICL before spending 3 years at the BBC. In 1999 he joined 3i as an investor in European technology based in London and Amsterdam. In 2002 he moved to Foursome Investments (now Frog Capital) as the lead investor of two funds, an environmental technology fund and a later stage development capital fund. David joined Close Ventures in 2005 and became a partner in Albion Ventures in 2009. David has a BSc in Economics from Warwick University.

Sam Gray

Sam joined Apposite Capital in 2007. He has been particularly involved in all of Apposite’s healthcare services and health IT investments and served on portfolio Boards in both the US and Europe. In addition to Mirada Medical, Sam currently serves on the Board of Medical Imaging Partnership, MC Care Holdings, Summit Medical, Swanton Care and was a Board Director of CancerPartnersUK, By the Bridge, SureCalm and WellPartner. Sam has been involved in deal-making in the healthcare sector since 2000 when he joined Deutsche Bank’s mergers and acquisitions practice, working with a number of multinational clients on corporate divestitures and acquisitions, including public takeovers and leveraged buy-outs. Sam then joined the Business Development team at Belgian pharmaceutical company, UCB, where he was instrumental in global product licensing and M&A, including UCB’s $2.7bn acquisition of the UK public biotech company, Celltech. Sam has a first degree in Natural Sciences and a masters degree in Chemistry from Cambridge University, as well as an MBA from Harvard Business School.

Hugh Bettesworth

Chief Executive

Paul Meskell

VP Marketing and Business Development (APAC)

Neil Stevenson

Software Development Manager

Mark Gooding

Chief Scientist

Sarah Bond

VP Product Management

Anna Griffin

Head of Finance, UK HR and Admin

Dave Lach

Vice President of Sales, North America

(858) 774-4222 l

Peter Bannister

VP Clinical Innovation

Prof. Amato J. Giaccia – Chair

Dr. Amato J. Giaccia obtained his Ph.D. in Pathology/Molecular Biology from the University of Pennsylvania in Philadelphia.  He is currently the Director of the MRC and CRUK funded Institute of Radiation Oncology at Oxford University in the UK.  He is also Professor Emeritus at Stanford University. At Stanford, he was Professor of Radiation Oncology, Associate Chair for Research & Director of the Division of Radiation & Cancer Biology in the Department of Radiation Oncology.  He also was the Director of Basic Science at the Stanford Cancer Institute and headed the Radiation Biology Program in Stanford’s Cancer Center.  He was awarded an American Cancer Society Junior Faculty Research Award and the Michael Fry Award from the Radiation Research Society for his outstanding contributions on understanding the molecular mechanisms of resistance promoted by the tumor microenvironment.  Additionally, he was the recipient of the 2013 ASTRO Gold Medal.  In 2015, he was awarded an NIH R35 Outstanding Investigator Award and was inducted into the National Academy of Medicine.  He co-authored the sixth, seventh & eighth editions of the textbook, “Radiation Biology for the Radiologist,” with Professor Eric Hall from Columbia.  In addition, he also held the “Jack, Lulu and Sam Willson Professorship in Cancer Biology” in the Stanford University School of Medicine.

Prof. Carlo Greco

Since 2011 Prof. Greco is the incumbent Director of Clinical Research at the Champalimaud Centre for the Unknown (CCU), a translational cancer research institute based in Lisbon. With his team, he has conduced several research studies of extreme hypofractionation and single dose radiation therapy in limited oligometastatic disease  with PET/CT confirmation of long-term complete response in over 90% of lesions treated with SDRT. In 2019 his research in the field of oligometastatic disease culminated in the identification of patients that will most likely benefit from ablative treatment based on pre-treatment clinical and metabolic parameters derived from PET scanning, thus improving optimization of resources and treatment cost-effectiveness.  He is also actively engaged in the management of early stage primary disease with cutting-edge technology and investigator–driven clinical studies using advanced organ motion mitigation techniques and target tracking in various disease settings such as lung and prostate cancer. In prostate cancer, in particular, he has developed an innovative technique that enables the delivery of a single ablative dose of radiation as a viable and non-invasive alternative to surgery. Preliminary results of a randomized clinical study comparing the established five session regimen versus a single ablative exposure in localized prostate cancer  have been presented at international meetings. He is currently involved in the introduction  of AI as a tool to improve accuracy in target volume definition and to predict likelihood of response to treatment thereby permitting identification of patients who may require further treatment.


Dr. Dan Fass

I have thirty-five years clinical experience in Radiation Oncology and was part of the pioneering team that developed both 3D RT and IMRT at Memorial Sloan Kettering Cancer Center. I later brought this technology to community hospitals in the New York area.

Recognizing the global need for access to state of the art radiation therapy services I was chosen as CEO for Princeton Healthcare Alliance. We are opened and manage a radiation oncology facility in Kazakhstan and consult through Central Asia, the Commonwealth of Independent States, GCC countries and Africa. Our team has extensive experience in the design, finance and operation of multi-speciality healthcare facilities.

We work with government ministries, lenders and providers to find site specific cost-effective solutions to benefit patients who would otherwise lack appropriate treatment.

We partner with companies that bring new technology to improve outcomes in the US market, offering practical solutions including AI and ML, working with both major academic institutions and small community practices to enhance value across the enterprise

Prof. Fei-Fei Liu, MD, FRCPC

Dr. Fei-Fei Liu is the Chief of the Radiation Medicine Program and Head of the Department of Radiation Oncology at the Princess Margaret Cancer Centre, as well as the Professor and Chair of the Department of Radiation Oncology at the University of Toronto. Dr. Liu is also a Senior Scientist at the Princess Margaret Cancer Research Institute, holds the inaugural University of Toronto/Princess Margaret Peter and Shelagh Godsoe Chair in Radiation Medicine, and as well, serves as the Chair of the Medical Advisory Board at the University Health Network.

Dr. Liu’s research program has been focused on investigating and developing novel molecular therapeutic strategies for human malignancies, delivered in conjunction with radiation therapy, along with investigating molecular aberrancies of several human malignancies including breast, and head/neck cancers. Dr. Liu has over 190 peer-reviewed publications on these topics, and has filed three patents. She currently holds peer-reviewed research funding from agencies including the Canadian Institutes of Health Research (CIHR) and the Canadian Cancer Society Research Institute (CCSRI). She is also the founding Director of a $1.9M Terry Fox Foundation Research Training Initiative, entitled “Strategic Training in Transdisciplinary Radiation Science for the 21st Century (STARS21)”, with the objective to train the next generation of trans-disciplinary scientists in Radiation Medicine.  Recently, her lab has shifted its focus to unraveling the mechanisms and identifying therapeutic strategies of radiation fibrosis and lymphedema; two important late normal tissue toxicities with significant functional morbidity.

Dr. Penny Kechagioglou

Dr Penny Kechagioglou is the Chief Medical Officer at GenesisCare UK and has joined the company in February 2018.  She is responsible for providing clinical leadership to the UKLT, driving innovation and research with the support of the clinical leaders forum and the clinical reference groups. In collaboration with the UKLT, she is leading the GenesisCare UK quality framework to ensure compliance and a culture of continuous Quality Improvement.

Dr Kechagioglou has an active public and private practice as a Consultant Clinical Oncologist, with a specialist interest in Breast cancer, Acute Oncology and Clinical Innovations. She has served as Clinical Governance Lead in the NHS, Vice Chair and member of NHS Research Ethics Committees and as member of the NICE Health Technology Assessment Committee. She is also a Specialist Advisor for the Care Quality Commission and the Healthcare Ombudsman and has served as Senior Clinical Lecturer in England and Scotland, Academic Mentor, Undergraduate and Postgraduate educator.

Dr Kechagioglou has been awarded an MSc in Public Health/Health Management from the University of London and an MBA from Bradford University. She is currently working toward a Doctorate in Business Administration at Warwick Business School, researching the optimal Innovation adoption and diffusion model in the healthcare sector, by studying and comparing Innovation processes in the public and private healthcare organisations.

Dr. Ed Holupka

Edward J Holupka is Chief, Division of Medical Physics at Harvard Medical School and Assistant Professor of Radiation Oncology, Department of Radiation Oncology at Beth Israel Deaconess Medical Center. Following postdoctoral appointments at the University of Geneva and the Joint Center for Radiation Therapy, he was subsequently Chief of Treatment Planning at Harvard Medical School.

With a broad background in radiation oncology, including specific training and expertise in Imaging, his research includes ultrasound imaging for prostate cancer, image fusion, prostate radioactive seed therapy, and recently deep learning for medical imaging. His group was the first to publish a paper on intra-operative treatment planning for which he wrote and designed the software, licensed to Burdette Medical Systems (BMSI) and later to Elekta Medical Systems.


Dr. Marc Posner

Dr. Marc Posner serves as the Medical Director of the department of Radiation Oncology at Northwestern Lake Forest Hospital just north of Chicago. Originally from New York City, Dr. Posner is Harvard trained and has over 17 years’ experience practicing as a Radiation Oncologist. His internship was completed in the University of Chicago Hospital system, followed by residency at the University of California in San Francisco, serving as the Chief Resident in 1999.

Dr. Posner joined the Lake Forest Hospital staff in 2000. His special interests include highly conformal radiotherapy with IMRT, VMAT, and IGRT as well as stereotactic radiotherapy and radiosurgery (SBRT/SRS). He is an expert in the treatment of prostate cancer, as well as malignancies of the head and neck, gastrointestinal tract, breast, brain and lung, all of which are best approached with these newest radiation techniques. He has additional training and experience in the treatment of other cancers, and constantly works to improve outcomes and reduce side effects. He has lectured both nationally and internationally on the use of advanced radiotherapy techniques in the treatment of prostate, head and neck, breast, and other cancers.

He is happily married with twin children and twin dogs (a pair of pairs!).

Prof. Philip Poortmans

In 1986 I completed my medical studies at the University of Antwerp, Belgium. I was trained as a radiation oncologist at the Middelheim and Vincentius Hospitals in Antwerp. In 1991 I started as a radiation oncologist in Tilburg (Netherlands). After chairing for 2.5 years the department of radiation oncology of the Radboud umc, Nijmegen, I took the same position at Institut Curie, Paris, France, in March 2017. On the 150th birthdate of Marie Curie I was nominated Marie Curie Professor Paris Science & Lettres – Institut Curie.

My Special interests include: breast cancer, quality assurance in clinical trials, malignant lymphoma and rare tumours. In 2005 I completed a PhD thesis on quality assurance in clinical trials in breast cancer at the University of Maastricht. Since 1992 I have been active in the EORTC,  and currently member of the Radiation Oncology (secretary 2006-2015), Lymphoma and Breast Groups. Previously I was a member of the Quality Assurance Committee of the EORTC (2003-2015), councillor of the board of ESTRO (2005 – 2008),  representative for radiation oncology in the Multidisciplinary Oncology Committee of ESMO (2007 – 2010), President-Elect (2013-2014) President (2014-2016) and Past-President (2016-2018) of ESTRO.(2013-2014), Chair of the ECCO Oncopolicy Committee (2016 – 2017), President-Elect (2017) President (2018-2019) and  Past-President (2020) of ECCO.

I am Director of the ESTRO School of Radiotherapy and Oncology “Multidisciplinary Management of Breast Cancer” and “Accelerated Partial Breast Irradiation” teaching courses. Honorary memberships include BVRO/ABRO , ESSO , SEOR, AROI, BIGOSA and JASTRO. In 2011 and 2012 I was nominated as “Toparts” (Outstanding doctor) by the Dutch radiation oncologists.

Prof. Sir Michael Brady

Prof. Sir Michael Brady FRS, FREng, FMedSci is now Professor of Oncological Imaging in the Department of Oncology at the University of Oxford, having retired in 2010 as Professor of Information Engineering. He is co-Director of the Oxford Cancer Imaging Centre. He combines his work in oncology with a range of entrepreneurial activities. He is Deputy Chairman of Oxford Instruments plc. and also a founding director of successful startup companies such as Guidance and, of course, Mirada Medical. He was elected an Honorary Fellow of the IET and Institute of Physics. He was awarded the IEE Faraday Medal in 2000 and also the IEEE Third Millennium Medal for the UK. In 2005 the Royal Institution awarded Professor Sir Michael Brady the Henry Dale Prize for “outstanding work on a biological topic by means of an original multidisciplinary approach”.

Dr. Thomas Buchholz, M.D

Thomas Buchholz, M.D., is Medical Director of the Scripps MD Anderson Cancer Center – a comprehensive and clinically integrated cancer care program.  He holds the endowed Conrad Prebys Executive Medical Directors at Scripps.

As a radiation oncologist with a clinical focus on breast cancer, Dr. Buchholz has made significant scientific and academic contributions over the course of his career.  His research in the area of breast cancer has been published in more than 350 peer-reviewed journals.

Dr. Buchholz comes to San Diego after spending 20 years in Houston at The University of Texas MD Anderson Cancer Center where he held a variety of academic and executive leadership positions with MD Anderson, including division head and department chair of radiation oncology, and serving as Executive Vice President and Physician-in-Chief.